Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a
Jun Yi Wang1, Yong Mei Hu2, Jian Xiong Liu1
1Affiliated with Chengdu Second People's Hospital, Qinyun South Road, 10th Avenue, Chengdu, 610041, Sichuan, China.
Insights
Congestive heart failure is a rare complication of acromegaly. Cardiac resynchronization therapy effectively treated severe heart failure in a patient with acromegaly when other treatments failed.
Area of Science:
- Cardiology
- Endocrinology
Background:
- Congestive heart failure (CHF) is uncommon in acromegaly, a condition caused by excessive growth hormone (GH) and insulin-like growth factor 1 (IGF-1).
- GH/IGF-1 excess can lead to myocyte dysfunction, impaired contractility, and vascular changes, potentially causing cardiac dysfunction over time.
- Early diagnosis of acromegaly-induced cardiomyopathy is crucial but often delayed due to the condition's insidious nature.
Observation:
- A 49-year-old male with acromegaly presented with decompensated systolic heart failure and severe left ventricular dysfunction (ejection fraction 16%).
- Electrocardiograms revealed a wide QRS duration (160-200 ms) with left bundle branch block.
- Standard treatments including stereotactic radiosurgery and pharmacotherapy showed minimal effect.
Findings:
- Cardiac resynchronization therapy (CRT) was successfully performed.
- CRT led to biventricular synchronization and mitigated reverse remodeling.
- The patient's heart failure symptoms significantly improved, allowing for hospital discharge.
Implications:
- Cardiac resynchronization therapy can be a valuable treatment for advanced acromegalic cardiomyopathy with heart failure.
- While curative treatments aim to normalize GH/IGF-1, CRT offers symptomatic relief and improved outcomes in severe cases.
- Further research into early diagnosis and management strategies for acromegaly-induced heart failure is warranted.
Background:
Congestive heart failure is rarely observed in patients with acromegaly. Excessive growth hormone secretion and elevation of insulin-like growth factor 1 contribute to pathological changes in myocyte growth and structure, cardiac contractility, vascular function, and in later stage may progress to cardiac dysfunction. Early recognition of the condition is paramount, though the insidious progression of the disease commonly results in late diagnosis. Current standard regimens of pharmacological therapy, surgical treatment, radiotherapy are designed to normalize serum levels of both insulin-like growth factor 1 and growth hormone. In patients with late-stage heart failure due to acromegalic cardiomyopathy, cardiac resynchronization therapy might be a desirable treatment to help cardiac synchronization, improve symptoms, and eventually reduce hospital admissions together with mortality rates.
Case Presentation:
We describe a case of a 49-year-old man with a history of acromegaly who presented to our hospital with a diagnosis of decompensated systolic heart failure. Serial electrocardiograms showed wide (160-200 ms) QRS duration with left bundle branch block. Echocardiography showed severe left ventricular dysfunction that simultaneously achieved a left ventricular ejection fraction of 16%. Surgical indication was rarely assessed by neurosurgeons. Given that the stereotactic radiosurgery together with pharmacotherapy produced infinitesimal effects, cardiac resynchronization therapy was performed. Owing to biventricular synchronization and holding back reverse remodeling, the patient's symptoms were successfully alleviated, and he was discharged from the hospital.
Conclusions:
Congestive heart failure is a rare complication in acromegaly-induced cardiomyopathy (occurs in only 3% of patients). Early diagnosis and treatment with curative drugs more than cardiovascular implantable electronic devices might lead to better surgical outcomes in this group of patients.
More Related Videos
10:08Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
Published on: February 17, 2018
09:16Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
Published on: February 28, 2018
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management
